March 8, 2010
Otsuka Pharmaceutical Co., Ltd.
In-vitro Diagnostic Kit, WT1 mRNA Assay Kit "Otsuka" Application Filed for Additional Purpose of Use with Myelodysplastic Syndromes
Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto) today announced that it filed an application to the Ministry of Health, Labour and Welfare (MHLW) in February 2010, for the addition of myelodysplastic syndromes as a purpose of use for its WT1 mRNA Assay Kit "Otsuka", an in-vitro diagnostic kit.
Information in this news release was current as of the original release date.